Kuros Biosciences Appoints Chris Fair as Chief Operating Officer - Seite 2
Mr. Fair currently sits on the Institute for Bioengineering and Bioscience Advisory Board of the Georgia Institute of Technology, as well as the boards of several privately held medical and regenerative medicine technology companies. He holds a degree in Business Administration from the University of Richmond's Robins School of Business.
For further information, please contact:
Kuros Biosciences AG Michael Grau Chief Financial Officer t: +41 44 733 47 47 e: michael.grau@kurosbio.com |
LifeSci Advisors Sandya von der Weid Media & Investors t: +41 78 680 05 38 e: svonderweid@lifesciadvisors.com |
Lesen Sie auch
About Kuros Biosciences
Kuros Biosciences is a fast-growing leader in the development of spinal fusion biologics that ease the burden of back pain. With locations in the United States, Switzerland and the Netherlands,
the company is listed on the SIX Swiss Exchange. The company’s first commercial product, MagnetOs, is a unique synthetic bone graft that has already been used successfully across three
continents and in over 10,000 spinal fusion surgeries. The next candidate in the Kuros pipeline is Fibrin-PTH – the first drug-biologic combination for interbody spinal fusions, currently
undergoing a Phase 2 clinical trial in the U.S. For more information on the company, its products and pipeline, visit
Forward Looking Statements
This media release contains certain forward-looking statements that involve risks and uncertain- ties that could cause actual results to be materially different from historical results or from
any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other
simi-lar words to be uncertain and forward-looking. Factors that may cause actual results to differ ma-terially from any future results expressed or implied by any forward-looking statements
include scientific, business, economic and financial factors. Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no
responsibility for updating forward-looking statements or adapting them to future events or developments.